Family Medicine Doctors in Pawnee City, NE Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 George R. Voigtlander, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 600 I St, Pawnee City, NE 68420 Phone: 402-852-2231 |
Richard E Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 600 I St, Pawnee City, NE 68420 Phone: 402-852-2011 |
Dr. Kent Joseph Niss, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 I St, Pawnee City, NE 68420 Phone: 402-852-2231 |
News Archive
Study on RNAi technology targeting neurodegenerative diseases
Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.
New study aims to prevent bacterial infections in sub-Saharan African kids
Bacteria infections - most of which are preventable via vaccines readily available in the developed world - and not malaria are the leading cause of death for children in sub-Saharan Africa. A new Michigan State University project based in Nigeria and funded by a $5.8 million grant aims to help prevent these diseases by collecting local data on the ailments, spurring vaccine use and development. Funded by the Bill & Melinda Gates Foundation, the research led by Stephen Obaro focuses on diseases such as pneumonia, sepsis and meningitis.
Study shows how variations in receptor genes may lead to obsessive-compulsive disorder traits
A new Northwestern Medicine study found evidence suggesting how neural dysfunction in a certain region of the brain can lead to obsessive and repetitive behaviors much like obsessive-compulsive disorder.
Can-Fite's CF102 decreases HCV viral load in liver cancer patients
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.
› Verified 9 days ago